WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561639

CAS#: 2137-18-0

Description: Gestonorone is a steroidal progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups that was never marketed.

Chemical Structure

CAS# 2137-18-0

Theoretical Analysis

MedKoo Cat#: 561639
Name: Gestonorone
CAS#: 2137-18-0
Chemical Formula: C20H28O3
Exact Mass: 316.20
Molecular Weight: 316.440
Elemental Analysis: C, 75.91; H, 8.92; O, 15.17

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Synonym: Gestonorone; 17alpha-Hydroxy-19-norprogesterone;

IUPAC/Chemical Name: (8R,9S,10R,13S,14S,17R)-17-Acetyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one


InChi Code: InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1

SMILES Code: O=C1CC[C@]2([H])[C@@]3([H])CC[C@]4(C)[C@@](O)(C(C)=O)CC[C@@]4([H])[C@]3([H])CCC2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 316.440000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Asadi E, Azodi-Deilami S, Abdouss M, Khaghani S. Cyproterone synthesis, recognition and controlled release by molecularly imprinted nanoparticle. Appl Biochem Biotechnol. 2012 Aug;167(7):2076-87. doi: 10.1007/s12010-012-9748-y. Epub 2012 Jun 5. PubMed PMID: 22669687. 2: O'Brien JM, Lewis DF. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. J Reprod Med. 2009 Feb;54(2):73-87. Review. PubMed PMID: 19301570. 3: Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med. 2009 Feb;54(2):47-52. PubMed PMID: 19301566. 4: Gomez F, Ruiz P, Briceño F, Lopez R, Michan A. Treatment with progesterone analogues decreases macrophage Fcgamma receptors expression. Clin Immunol Immunopathol. 1998 Dec;89(3):231-9. PubMed PMID: 9837693. 5: Lipp R, Laurent H, Günther C, Riedl J, Esperling P, Täuber U. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm Res. 1998 Sep;15(9):1419-24. PubMed PMID: 9755895. 6: Iguchi H, Ikeuchi T, Kai Y, Yoshida H. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism]. Hinyokika Kiyo. 1994 Mar;40(3):215-9. Japanese. PubMed PMID: 7513937. 7: Altwein JE, Almer F. Is there a change in the treatment of benign prostatic hyperplasia? Urol Int. 1994;52(1):1-3. PubMed PMID: 7511260. 8: Lang R, Reimann R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ Mol Mutagen. 1993;21(3):272-304. PubMed PMID: 8462531. 9: Di Silverio F, D'Eramo G, Flammia GP, Buscarini M, Frascaro E, Mariani M, Sciarra A. [Pharmacological combinations in the treatment of benign prostatic hypertrophy]. J Urol (Paris). 1993;99(6):316-20. Review. French. PubMed PMID: 7516378. 10: Kanimoto Y, Okada K. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results]. Hinyokika Kiyo. 1991 Nov;37(11):1423-8. Japanese. PubMed PMID: 1722627. 11: Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, Shani A, Servadio C, Stein JA. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod. 1987 Dec;6(6):610-24. PubMed PMID: 3330126. 12: Runge HM, Neumann HA, Bauknecht T, Pfleiderer A. Growth patterns and hormonal sensitivity of primary tumor, abdominal metastasis and ascitic fluid from human epithelial ovarian carcinomas in the tumor colony-forming assay. Eur J Cancer Clin Oncol. 1986 Jun;22(6):691-6. PubMed PMID: 3743604. 13: Di Silverio F. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate]. Minerva Urol Nefrol. 1986 Apr-Jun;38(2):163-71. Italian. PubMed PMID: 2428120. 14: Latalski M, Obuchowska D. [Ultrastructure of secretory cells of the bulbourethral glands of rats after experimental inhibition of the gonadotropic function of the pituitary gland]. Ann Univ Mariae Curie Sklodowska Med. 1986;41:139-44. Polish. PubMed PMID: 3154049. 15: Runge HM, Teufel G, Neulen J, Geyer H, Pfleiderer A. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol. 1986;16(1):58-63. PubMed PMID: 2933176. 16: Baranowska B, Kuzaka B. [Treatment of benign prostatic hypertrophy with gestonorone caproate]. Pol Tyg Lek. 1984 Jul 16-23;39(29-30):999-1003. Polish. PubMed PMID: 6209689. 17: De Palo G, Spatti GB, Bandieramonte G, Luciani L. Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion. Tumori. 1983 Feb 28;69(1):65-7. PubMed PMID: 6836750. 18: Moazzami B, Van der Walt JD, Boyd NR. Use of progestogens as an adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus. Br J Obstet Gynaecol. 1983 Feb;90(2):178-81. PubMed PMID: 6218817. 19: Latalski M, Obuchowska D, Spruch T. [Study of the ultrastructure of epithelial cells of the seminal vesicles of rats after inhibition of the gonadotropic function of the anterior pituitary gland]. Ann Univ Mariae Curie Sklodowska Med. 1983;38:155-62. Polish. PubMed PMID: 6600062. 20: Turner GA, Ellis RD, Guthrie D, Latner AL, Ross WM, Skillen AW. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy. Br J Obstet Gynaecol. 1982 Sep;89(9):760-4. PubMed PMID: 6288064.